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Cancer is increasingly perceived as a systems-level, network 
phenomenon. The major trend of malignant transformation can be 
described as a two-phase process, where an initial increase of network 
plasticity is followed by a decrease of plasticity at late stages of tumor 
development. The fluctuating intensity of stress factors, like hypoxia, 
inflammation and the either cooperative or hostile interactions of tumor 
inter-cellular networks, all increase the adaptation potential of cancer 
cells. This may lead to the bypass of cellular senescence, and to the 
development of cancer stem cells. We propose that the central tenet of 
cancer stem cell definition lies exactly in the indefinability of cancer 
stem cells. Actual properties of cancer stem cells depend on the 
individual “stress-history” of the given tumor. Cancer stem cells are 
characterized by an extremely large evolvability (i.e. a capacity to 
generate heritable phenotypic variation), which corresponds well with 
the defining hallmarks of cancer stem cells: the possession of the 
capacity to self-renew and to repeatedly re-build the heterogeneous 
lineages of cancer cells that comprise a tumor in new environments. 
Cancer stem cells represent a cell population, which is adapted to adapt. 
We argue that the high evolvability of cancer stem cells is helped by 
their repeated transitions between plastic (proliferative, symmetrically 
dividing) and rigid (quiescent, asymmetrically dividing, often more 
invasive) phenotypes having plastic and rigid networks. Thus, cancer 
stem cells reverse and replay cancer development multiple times. We 
describe network models potentially explaining cancer stem cell-like 
behavior. Finally, we propose novel strategies including combination 
therapies and multi- target drugs to overcome the Nietzschean dilemma 
of cancer stem cell targeting: “what does not kill me makes me 
stronger”. 
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. Cancer as a network development disease
Malignant transformation is increasingly described as a
ystems-level, network phenomenon. Both healthy and tumor
ells can be perceived as networks. Nodes may  be the amino
cids of cancer-related proteins, where edges are related to sec-
ndary chemical bonds. Nodes may  also be defined as protein/RNA
olecules or DNA-segments, where edges are their physical or
ignaling contacts. In metabolic networks, nodes are metabolites
nd edges are the enzymes, which catalyze the reactions to con-
ert them to each other [1–3]. Most of the statements of this review
ay  characterize all these molecular networks of tumor cells and
ancer stem cells.
As stated already by Virchow in 1859 [4], cancer is a devel-
pmental process. Cancer cells are products of a complex series
f cell transformation events. The starting steps are often muta-
ions or DNA-rearrangements, which destabilize the former cellular
henotypes. As a result, a cell population with a large variability in
hromatin organization, gene expression patterns and interactome
omposition is formed [5–9]. In this process, changes in network
tructure and dynamics play a crucial role.
This review will focus on the large-scale network rear-
angements during cancer development—and the emergent,
ystems-level changes they develop. We  will show that changes in
etwork plasticity (and its opposite: network rigidity) may  explain
entral tenets in both cancer development and cancer stem cell
ehavior. Network plasticity (or in other words network flexibility)
an be defined at the level of both network responses and structure
7,10] as it will be detailed in Section 2.
. Malignant transformation proceeds via states
haracterized by increased and decreased network plasticity
.1. Initial increase of network plasticity is followed by a decrease
f network plasticity at late stages of carcinogenesis
In our earlier works [3,11,12], summarizing several pieces of evi-
ence we proposed that malignant transformation is a two-phase
rocess, where an initial increase of network plasticity is followed
y its decrease at late stages of carcinogenesis. The phenotype of
he already established, late-stage cancer cells is still more plastic
nd immature than that of normal cells, but may  often be more
igid than the phenotype of the cells in the intermediate stages of
arcinogenesis.
In this concept, network plasticity (or in other words functional
etwork flexibility) can be determined either at level of network
esponses (network dynamics, attractor structure) and at the level
f network structure. The network has a high plasticity at the level
f its responses, if small perturbations induce large changes in
etwork structure and dynamics [7,10]. At the level of network,
tructure network plasticity depends on the internal degrees of
reedom of network nodes. Degrees of freedom are reduced by
ense clusters, like cliques, or by intra-modular node position.
egrees of freedom are also related to specific network properties:
.g. in transportation-type networks (like metabolic networks) an
dditional edge may  increase the degree of freedom, while in con-
ection type networks (like interactomes) an additional edge may
ecrease the degree of freedom. The numerical characterization
f network plasticity both at the network response and network
tructure levels is an exciting area of current studies (see more in
10]).Sources and signs of the initial increase of network plasticity in
ancer development are summarized in Table 1 [5,7,13–30]. These
ources and signs are related to each other, and might not happen
ndependently. Moreover, Table 1 shows a self-amplified growthcer Biology 30 (2015) 42–51 43
of network disorder during tumor development. Self-amplification
occurs, when the increased disorder of nodes causes a disorder
of their networks, which amplifies the disorder of the nodes fur-
ther. These synergistic processes cause an accelerated decrease
of system-constraints, with a parallel increase in entropy and the
degrees of freedom both at the level of the individual nodes and
their networks. All these changes lead to the development of more
plastic cellular networks in the early phase of cancer. The early stage
of cancer development, characterized by an increase of network
plasticity, may  correspond to the “clonal expansion” phase and the
appearance of tumor initiating cells. Such plasticity increase may
characterize multiple clonal expansions occurring in some cancer
types.
Late stage carcinogenesis is characterized by a decrease of
network plasticity reflected by decreasing entropy both at the inter-
actome and signaling network level (such as in case of comparing
colon carcinomas to adenomas; Hódsági et al. and Módos et al.,
unpublished observations). Late stage tumor cells may  represent
either late stage primary tumor cells, or metastatic cells, which
already settled in their novel tissue environment. These findings are
in agreement with the recent data of Aihara and co-workers [31,32]
showing a transient decrease of entropy of human bio-molecular
interaction network during B cell lymphoma, hepatocellular carci-
noma and chronic hepatitis B liver cancer development. It is yet to
be shown, whether the other types of plasticity increases listed in
Table 1 for early stage cancer cells are also reversed in late stage
cancer cells.
The dual changes described above correspond well to vari-
ous steps in the transition to the cancer-specific states, termed
as “cancer attractors” by Stuart Kauffman in 1971 [33]. Cancer
cells have to first cross a barrier in the quasi-potential (epige-
netic) landscape. This barrier might be lowered by mutations or
epigenetic changes [5], but its bypass requires a transient desta-
bilization of the transforming cell. This destabilization leads to a
more plastic phenotype. This is followed by the stabilization of
the cancer cell in the cancer attractor invoking a more rigid phe-
notype. Importantly, the attractor structure itself may  undergo
gross changes during cancer development, due to changes in
network structure, dynamics and interactions with the environ-
ment.
The increase and decrease of network entropy resembles to
that observed in cell differentiation processes, where an initial
increase of entropy of co-regulated gene expression pattern was
followed by a later decrease [34]. An analogous set of events
happens in cellular reprogramming, where an early, very hetero-
geneous, stochastic phase is followed by a late phase, which is
programmed by a hierarchical set of transcription factors [35]. Plas-
tic/rigid phenotypes of early/late phases may correspond to the
proliferative/remodeling phenotypes of cancer cells obtained by
gene expression signature analysis [36]. Importantly, the prolife-
rative/remodeling phenotype duality is very similar to the duality
of proliferative/quiescent states of cancer stem cells, which we  will
discuss in Section 3.
2.2. Increase and decrease of network plasticity may  alternate in
cancer development
The initial increase and later decrease of network plasticity is
not displayed uniformly by the heterogeneous cell populations of
tumors. Tumors may  harbor early phase (plastic) and late phase
(rigid) cells at the same time. Importantly, cancer cells in late phase
may  switch back to an early phase of development [7,26,28]. Thus,
tumor cell populations may  often be characterized by reversible
switches between plastic and rigid network states. Cancer stem
cell networks may  alternate between plastic and rigid states very
intensively, as we  will describe in Section 3.
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Table 1
Sources and signs of increased network plasticity in cancer development.
Source/sign of increased network plasticity References Rationale
More intrinsically unstructured proteins [13,16,27] The increased “conformational noise” of individual proteins makes
protein–protein interactions, signaling and metabolism fuzzier in cancer cells
Genome instability, chromosomal anomalies [7] Destabilization of DNA and chromatin structure, as well as chromosomal
anomalies are both consequences and sources of increased system disorder
Larger noise of network dynamics (including that of signaling
and metabolic networks, as well as larger fluctuations of
steady-state values and sensitivity thresholds inducing
more stochastic switch-type responses)
[5,14,21] The larger noise of system dynamics is both a sign of increased network
plasticity at the “bottom network” level and a source of further increase in
network plasticity at the “top network” level, thus works as a self-amplifier
(“bottom networks” describe nodes of the “top networks” like protein
structure networks describe nodes of interactomes)
Increased entropy of protein–protein interaction and
signaling networks
[18–20,23] The increased entropy of various networks extends the increased disorder of
the  elementary processes to the system level
Larger physical deformability of cancer cells and larger shape
heterogeneity
[15,25,30] Larger cellular deformability shows an increased disorder at the level of the
cytoskeletal network, and contributes to chromosomal damage increasing the
cellular disorder further. Active mechanisms changing cells from rounded to
elongated shape or vice versa increase structural diversity further
Alternating symmetric and asymmetric cell division of cancer
stem cells
[17,24,29] Asymmetric cell division increases cellular heterogeneity. Its environmentally
regulated alternating character is both a sign and source of increased diversity
and plasticity of both intra- and inter-cellular networks
Heterogeneous cellular responses to the same stimuli,
increased cellular heterogeneity (of tumor cells and
infiltrating lymphocytes, macrophages, mast cells,
epithelial cells, endothelial cells, fibroblasts and stromal
[7,22,26,28] Cellular heterogeneity is both a sign of increased plasticity of intra-cellular
networks of tumor cells, and, via an increase of the heterogeneity of
inter-cellular signals of the tumor microenvironment, acts as a source of
further increase in system plasticity working as a self-amplifier
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.3. Fluctuating changes of tumor microenvironment may induce
n increased adaptation potential of cancer cells via their
lternating plastic and rigid network structures
Plasticity and rigidity changes of tumor cell networks are
ften provoked by changes in the environment of tumor cells.
e summarize the major environmental factors enhancing plas-
icity/rigidity transitions during cancer development in Table 2
22,26,28,37–64]. As shown in Table 2, inter-cellular networks
ften develop pro-oncogenic cooperation, but also give a contin-
ously changing environment increasing the adaptation potential
f cancer cells. Moreover, tumors grow in a hostile environment
haracterized by hypoxia, inflammatory responses, low pH, low
utrients, extensive necrosis and targeted by immune and ther-
peutic attacks. The continuous fluctuation of these stress factors
ncreases the adaptation potential of cancer cells further. Alternat-
ng changes in network plasticity and rigidity may  play a key role
n this “maturation” process. Environment-induced changes may
ead to the bypass of cellular senescence and to the development
f cancer stem cells (Table 2).
. Network modeling of cancer stem cells
.1. Definition(s) and properties of cancer stem cells
Cancer stem cells have been defined in an American Associa-
ion for Cancer Research workshop held in 2006 as “cells within
 tumor that possess the capacity to self-renew and to cause the
eterogeneous lineages of cancer cells that comprise the tumor”
65]. Table 3 lists a number of common beliefs on defining hall-
arks of cancer stem cells showing the question marks related to
he generalization of these hallmarks [17,26,47,65–78]. We  do not
onsider the uncertainties in the exact definition of cancer stem
ells as shortcomings of the field, or as unsolved questions. On the
ontrary, we think that the very essence of the nature of cancer stem
ells is their extreme plasticity, which prevents their precise defi-
ition other than ‘cells within a tumor that possess the capacity to
elf-renew and to repeatedly re-build the heterogeneous lineages
f cancer cells that comprise a tumor in new environments’. Thus,
he central tenet of the definition of cancer stem cells lies exactly
n their indefinability. This is why in this review we generally usethe term “cancer stem cell” instead of the large variability of names
in the literature.
Cancer stem cells have an extremely high adaptation potential
to different environments. Thus, the extremely high plasticity of
cancer stem cells can be expressed more precisely as an extremely
high ability to change the plasticity/rigidity of their networks. Such
a property is called metaplasticity in neuroscience [79] and evol-
vability in genetics [80]. Evolvability (i.e. “an organism’s capacity
to generate heritable phenotypic variation” [80]) is a selectable trait
[81], which is mediated by complex networks [82]. This gives us
hope that the network requirements of the extremely high evolva-
bility of cancer stem cells can be elucidated and used in anti-cancer
therapies in the future. We  will summarize the current view on can-
cer stem cell networks in Section 3.2 and suggest novel therapeutic
strategies in Section 4.
Three properties emerge as differentiating hallmarks of can-
cer stem cells from normal stem cells: (A) increased proliferative
potential with a loss of normal terminal differentiation pro-
grams; (B) increased individuality (increased niche-independence
or niche-parasite behavior); and (C) large efficiency in responses
of environmental changes. The high self-renewal potential of nor-
mal  stem cells gives yet another powerful tool of cancer stem cell
survival and evolvability [75,78].
Stemness, especially in tumors, is characterized by large unpre-
dictability, where the outcome is heavily dependent on the
individual “stress-history” (past changes of its environment) of the
given cancer stem cell. Indeed, more and more data support the
early view [83] that cancer stem cells require a number of environ-
mental changes to increase their tumorigenic potential.
• Performing the “defining experiment of cancer stem cells”, the
serial re-transplantation of tumor cells, for years in Drosophila
made the cells more tumorigenic with each round of transplan-
tation [84].
• Cancer stem cells could be de-differentiated from differenti-
ated tumor cells in an environment dependent manner [47,71].
Human somatic cells could be reprogrammed to unstable induced
epithelial stem cells, which could be transformed to pluripotent
cancer stem cells by serial transplantation [76]. Importantly, can-
cer stem cells were shown to transmit neoplastic properties to
normal stem cells [75]. Aged stem cells can be rejuvenated by
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Table  2
Environmental challenges provoking changes in network plasticity and rigidity in cancer development.
Environmental challenge Effects on cancer development and on network plasticity/rigidity References
Alternating cooperation and
competition of inter-cellular
networks of the tumor
microenvironment
Tumors harbor an extremely heterogeneous cell population of tumor cells,
immune cells, epithelial cells, endothelial cells, fibroblasts and stromal cells.
These cells may  form a cooperating inter-cellular network, and may  develop a
pro-oncogenic microenvironment. Stabilization of tumor microenvironment
shifts cellular networks towards a more rigid state. On the contrary, a
fluctuating environment provokes the development of more flexible networks.
[22,26,28,38,49,55,58,64]
Changes in the “embeddednes” of
tumor cells in the extracellular
matrix of tumor microenvironment
Cancer stem cells often occupy a special niche, where niche cells and cancer
stem cells mutually help each other’s survival by cell adhesion beyond soluble
factors. Cancer-associated fibroblasts help the development of a pro-oncogenic
microenvironment by a contact dependent mechanism. High molecular weight
hyaluronic acid emerges as a key regulator of tumor microenvironment.
Increased “embeddedness” of tumor cells in their extracellular environment
may increase the rigidity of their networks. (This is the case in the invasive
phenotype using extracellular contacts to migrate, and invade new niches, as
discussed in Section 3.2). On the contrary, increased independence from the
extracellular environment allows increased network plasticity.
[39,42,44,49,52,53,56,61,63]
Fluctuations in oxygen tension leading
to various degrees of hypoxia and to
a  large variability of hypoxia-related
responses
In agreement with the hypoxia-induced inhibition of senescence, stem cells
usually reside in the most hypoxic region of the respective tissue, and are
resistant to oxidative stress. Hypoxia-related networks are highly sensitive to
minor changes in oxygen concentration, which induces a large variability of
hypoxia-related responses. Thus, fluctuations of oxygen tension (which are
magnified in tumor microenvironment) may  play a key role in the
“maturation” of plasticity/rigidity network transitions, and thus the
development of cancer stem cells.
[40,41,46,51]
Fluctuating intensity of chronic
inflammation
Inflammation has a key role in all phases of tumor development. Inflammation
may transform stem cells to a more pluripotent, more aggressive phenotype
resembling that of cancer stem cells. The Toll-receptor related inflammatory
signaling network and its key players, such as MYD88, play an important role
in  cancer stem cell induction. The fluctuating intensity of chronic
inflammations may  increase further the adaptation potential of cancer cells
mediated by plasticity/rigidity-changes of their networks.
[22,43,57,59,60]
Cellular senescence and escape from
the senescent state
Although therapy-induced cellular senescence may  be beneficial, senescent
tumor cells have a number of harmful properties such as: production of
inflammatory cytokines and paracrine activators of cancer stem cells,
degradation of tumor microenvironment, as well as their potential re-entry to
the cell cycle. Escape from the senescent state is a major threat in tumor
progression. One of the mediators, survivin, protects senescent cells, may
reverse senescence, and characterizes cancer growth showing a co-expression
with cancer stem cell markers. Recent studies uncovered a set of highly
proliferative microRNAs (such as members of the miR302/367 and miR520
clusters) playing a major role in senescence bypass. Many of these changes
characterize cancer stem cells. Cells escaping therapy-induced senescence
display a number of proteins characteristic of cancer stem cells such as CD133
or  OCT4, and are characterized by an increased amount of antioxidant
arbor
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a systemic young environment [85], which raises the possibil-
ity that interactions between quiescent cancer stem cells and
their rapidly proliferating environment may  help the prolonged
survival of cancer stem cells.
Bioactive food components may  foster the aberrant self-renewal
of cancer stem cells influencing the balance between their proli-
ferative and quiescent phenotypes [86].
Anti-cancer therapy often induces a wound-healing response,
and contributes to the increase of tumorigenic potential of resid-
ual, surviving cancer stem cells [7,28,87].
Environmental changes can often be even more potent to
ncrease the tumorigenicity of cancer stem cells, if they have alter-
ating “turn-on” and “turn-off” phases. As an analogy, reversible
lternations of stem cell states (with parallel “up” and “down”
hanges of WNT  pathway activity) are required to prevent stem
ell senescence [88].
Partly due to the alternating environmental changes some can-
er cells reversibly undergo transitions among states that differ
n their competence to contribute to tumor growth (e.g. between
pithelial and mesenchymal states) [71,74,89]. Proliferative and
nvasive phenotypes were identified as distinct phenotypes of var-
ous cancers [36]. Melanoma cells often switch between these more rigid networks, while escape from
re-gained network plasticity.
phenotypes [90]. These phenotype transitions, often mediated by
genetic lesions, offer an increased chance to adopt a cancer stem
cell-like identity [91]. Drug resistance is also a plastic property of
some cancer cells. Multi-resistant cancer cell lines reversibly form
sensitive or resistant progeny depending on whether the cells are
passaged with or without the drug [92]. However, many of the
existing evidence for reversible transitions between tumorigenic
and non-tumorigenic states comes from studies of cells in culture,
and their significance has yet to be established in vivo [28].
Alternating and environment-dependent asymmetric and sym-
metric cell divisions (where template DNA strands are segregated
to the daughter cell destined to be a stem cell, or are divided
randomly) characterize cancer stem cells. These divisions may be
characterized further by the fate of the daughter cells continu-
ing to be stem cells or cells destined to differentiate. Asymmetric
lung or gastrointestinal cancer stem cell division is increased by
cell density, cell contacts or heat sensitive paracrine signaling, and
decreased by hypoxia or serum deprivation [17,24,29]. Asymmet-
ric division characterizes a rigid, quiescent state of cancer stem
cells carefully saving encoded information, while separating it from
cellular “garbage”. On the contrary, symmetric cell division of can-
cer stem cells characterizes their more plastic, responsive state
acquiring and encoding new information. This view is in agreement
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Table 3
Commonly believed cancer stem cell defining hallmarks—and their question marks.
Commonly believed cancer stem cell
defining hallmark
Question marks of hallmark References
Is able to form tumors in different
environments (especially when
using serial transplantation assays)
This definition is the original and most applicable definition of cancer stem
cells. Immuno-compromised mice, which are often used in transplantation
assay, still may  suppress certain tumorigenic cells by a wound-healing type
response, and may  miss several human cell types (forming the cancer stem cell
“niche”) needed for tumor development. Mouse-related test environments are
not fully informative of tumors in human patients.
[28,65–67,77]
Is the precursor of non-tumorigenic
cells of the original tumor
This was  considered as a consequence of the above definition. However
several lines of evidence suggest that the two statements may  be unrelated to
each other, and the hierarchical lineage typical to most normal stem cells does
not  characterize many cancer stem cells. Many types of tumors have a
surprisingly large genetic heterogeneity suggesting distinct cancer stem cell
populations within the same tumor. However, detailed measurement of the
tumorigenic potential of the various intra-tumor genotypes is largely missing.
Results of the few lineage tracing and selective cell-ablation experiments
could not be generalized so far.
[26,28,68,74]
Forms only a minor cell subpopulation
of tumors
Cancer stem cells may form a rare subpopulation of tumor cells. However, in
some experiments a high amount of cancer cells (e.g. 50% instead of the
original 0.0004%) were found tumorigenic.
[28,69,70,72–74,77]
Is derived from normal stem cells Though several experiments showed that normal stem cells can be
transformed to cancer stem cells, many cancer stem cells seem to be generated
from more differentiated cells.
[47,71,75–78]
Is resistant to therapy Therapies inducing cell differentiation successfully target some cancer stem
cells. Therapy survival seems to be a stochastic process often depending on de
novo mutations.
[28]
Can be characterized by various cancer
stem cell markers
A number of promising cancer stem cell markers (such as CD34, CD38, CD133,
CD271, Lgr5) were not generally applicable to the respective tumor type.
[28]
Undergoes asymmetric cell division Cancer stem cells seem to alternate between symmetric and asymmetric cell
divisions. This property, which depends on the environment of cancer stem
source
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cancer stem cells.
ith the findings that: (A) the tumor suppressor, p53 promoted
symmetric cell division of breast cancer stem cells [93] possibly
nhibiting their ability to cycle between asymmetric and symmet-
ic cell division forms; (B) block of asymmetric cell division led to
bnormal proliferation and genomic instability in Drosophila [94]
nd (C) rates of asymmetric cell division were different between
umors of a single tumor type [95], and may  have to be determined
ndividually for each tumor (or tumor cell).
Increase in asymmetric cell division is similar to the develop-
ent of the quiescent, cooperative state after quorum sensing,
hile increase in symmetric cell division is similar to quorum
uenching [96]. Thus, cancer stem cells may  have dedifferentiated
o the level that uses community regulation mechanisms similar to
hose of unicellular organisms, such as bacteria. However, it is an
pen question, whether inter-cellular cooperation of tumor cells
ncreases with increased asymmetric cell division of cancer stem
ells. The recent paper of Dejosez et al. [97] showed the existence
f a p53, topoisomerase 1 and olfactory receptor-centered molec-
lar network, which regulates the cooperation of murine induced
luripotent stem cells. It will be a question of later exciting stud-
es to examine whether this molecular network is involved in the
aintenance of asymmetric cell division beyond p53, which is a
ell-known promoter of cell division asymmetry [93].
As a summary, experiments revealed that cancer stem cells
re characterized by increased self-renewal potential; increased
roliferative potential with a loss of normal terminal differentia-
ion programs; increased individuality and by large efficiency in
esponses of environmental changes. The appearance and abun-
ance of cancer stem cells seem to be related to the stress-history
f the actual tumor. Cancer stem cells have two major phenotypes:
 proliferative and a quiescent state characterized by symmetric
nd asymmetric cell divisions, respectively. More and more stud-
es suggest that the less proliferative cancer stem cell phenotype is
haracterized by increased invasiveness [98–100]. As we will dis-
uss in Section 3.2, network changes may  explain this phenomenon. of the increased plasticity and evolvability of
In conclusion, as the major hypothesis of this review we
propose that the adaptation potential of cancer stem cells is
increased by repeated transitions between their plastic (prolife-
rative) and rigid (quiescent/often more invasive) phenotypes. The
major driving force behind these transitions is the changes in the
microenvironment of cancer stem cells (exemplified by the serial
transplantations in the defining experiment of cancer stem cells).
Thus, cancer stem cells seem to be able to reverse and replay can-
cer development multiple times. In cancer development cancer
stem cells are repeatedly selected for high evolvability, and became
“adapted to adapt” (Fig. 1).
3.2. Network models of cancer stem cells
In the last years, several network models of various types of
stem cells have been published. We  quote here only the work of
Muller et al. [101], where gene expression data of approximately
150 of different human stem cell lines were collected and analyzed.
Transcriptomes of pluripotent stem cells (embryonic stem cells,
stem embryonal carcinomas and induced pluripotent cells) formed
a tight cluster, while those of other stem cells were very diverse.
Pluripotent stem cells shared a joint sub-interactome, enriched in
NANOG, SOX2 and E2F-induced gene-products, as well as in pro-
teins related to “tumorigenesis” in a phenotype analysis [101].
Initial characterization of cancer stem cell-specific networks was
performed in osteosarcoma [102]. Gene products of the “stem-
transcription factors”, NANOG, SOX2, OCT4, KLF4 and MYC, as well
as members of the WNT, TGF-, Notch and Hedgehog pathways
emerged as key players of the cancer stem cell signaling network
with the concomitant down-regulation of p53, CDKN2A, PTEN, the
polycomb repressor complex (including BMI1) and miR-200, where
the latter showed an interplay with the ZEB transcriptional repres-
sors. Lacking extensive single cell data on cancer stem cell signaling
we currently do not have a clear picture of how many of these
mechanisms act simultaneously. However, several lines of evidence
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Fig. 1. “What does not kill me  makes me  stronger”: Environmental stress-induced alternation of plastic and rigid networks may  explain the extremely high evolvability of
cancer  stem cells. The figure illustrates the major hypothesis of the current review showing that a large variety of environmental stresses (such as hypoxia, inflammation and
anti-cancer therapy itself) and stress-responses (such as inflammatory responses and senescence of surrounding cells) may induce the alternation of plastic and rigid states
of  molecular networks of cancer stem cells. In these networks nodes may  be proteins or RNA molecules, while edges may represent their physical or signaling interactions.
Similar  plasticity/rigidity alterations may occur in metabolic networks (where nodes are small metabolites and edges are enzymes converting them to each other), or in
networks of larger cellular complexes, where nodes represent various microfilaments or cellular organelles (such as mitochondria) and edges stand for their interactions.
Alternating plastic and rigid network states may  help the maturation of cancer stem cells developing their larger adaptability, evolvability and long-term survival. Thus
the  proverbial saying of Nietzsche: “What does not kill me  makes me stronger” [7,125] is especially true for cancer stem cells, and involves the cycling of their molecular
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tetworks (such as interactomes, metabolic and signaling networks) between more p
he  creation of new nodes and edges, as well as changes of the weights of existing e
uggest that cancer stem cells harbor signaling circuits, which are
erially switched on and off in an alternating and cross-regulated
anner [76,78,86,103–108].
A number of complex model and real world networks undergo
brupt and extensive changes in their topology as a response
o a shortage of resources needed to maintain inter-nodal con-
ections and/or upon environmental stress. These changes are
alled network topological phase transitions and result in a mas-
ive re-organization of network structure, dynamics and function
109–112]. Since the environment of cancers provides an extreme
ariety of resource/stress levels, which are magnified further by
nti-cancer therapies, we have all reasons to assume that networks
f cancer cells respond to this environmental variability by topo-
ogical phase transitions rather often.
Table 4 describes several hypothetical network behaviors,
hich may  explain the extremely high evolvability of cancer stem
ells. These mechanisms are interrelated, and may  involve the dele-
ion of existing nodes and edges, creation of new nodes and edges,
s well as changes of edge weights. Highly dynamic, inter-modular
reative nodes may  break rigid network structures similarly to
attice defects. Increasing network core size or fuzziness, overlap-
ing, fuzzy network modules or larger intracellular water content
ay  all help this plasticity-increasing process. On the contrary,
igidity-seed nodes may  establish a rigid cluster, and rigidity-
romoting nodes may  help it to grow causing a rigidity phase
ransition. Decreased dynamics of creative nodes (including chap-
rones and prions), smaller network core size or more compact
etwork core, separated modules, decreasing intracellular water
ontent may  all help this rigidity-increasing process. As a con-
equence, increase of network plasticity shifts the state-space of
he network to a smoother quasi-potential (epigenetic) landscape,
hile the increase of network rigidity develops a rougher quasi-
otential (epigenetic) landscape [3,5,7,10–12,18,82,110,113–124].
These changes are related both to the alternating prolifera-
ive and quiescent cancer stem cell phenotypes (Fig. 1) and to the and more rigid states. Changes of rigid and plastic network structures may involve
as described in Table 4 in detail.
topological network phase transitions mentioned before. Impor-
tantly, the quiescent cancer stem cell phenotype often coincides
with the invasive phenotype [98–100]. It is rather plausible that
high mobility and invasiveness requires a more rigid network struc-
ture up to the level of cytoskeletal networks, since physical force
required for both migration and invasion can only be exercised effi-
ciently, if the underlying network is not plastic (Fig. 1). However,
more studies are needed to assess the generality of the association
of the quiescent and the more invasive cancer stem cell phenotypes.
4. Network-related drug targeting of cancer stem cells
Cancer stem cells follow Nietzsche’s proverbial saying “what
does not kill me  makes me  stronger” [125]. Thus, conventional
anti-cancer therapies may  actually provoke cancer stem cell devel-
opment [7,28,87]. However, in the last years a number of cancer
stem cell-specific therapies have been developed. Many of the key
nodes of cancer stem cell signaling network, such as members of
Hedgehog, WNT  and Notch pathways, as well as microRNAs, are
already used as targets of therapeutic interventions against cancer
stem cells. This repertoire is extended by antibodies against puta-
tive cancer stem cell markers [78,86]. Differentiation therapy was
first suggested by Stuart Kauffman in 1971 [33], and is increas-
ingly used to induce the differentiation of cancer stem cells [78].
Interactions of cancer stem cells with their environment may also
provide a panel of targets, like periostin, which is a component
of the fibroblast-expressed extracellular matrix [126]. Encourag-
ingly, recent data suggest that some commonly used clinical drugs,
such as chloroquine and metformin inhibit the mechanisms used
by cancer stem cells to over-ride cellular senescence [50].
Recently a dual drug target strategy, containing the central
hit strategy and the network influence strategy, was described to
target various diseases [3]. The central hit strategy damages the
network integrity of the rapidly proliferating cell in a selective man-
ner. This strategy is useful when attacking plastic networks. The
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Table 4
Hypothetical network-level explanations and possible network modeling approaches of cancer stem cell-like behavior.
Alternating network property inducing
more/less system plasticity
Its possible contribution to cancer stem cell behavior Possible network modeling approach References
(A) Changes in network topology and dynamics
Successive larger/smaller expression of
capacitors of evolvability including
creative network nodes
Highly dynamic, inter-modular creative nodes (and/or other capacitor
proteins of evolvability including molecular chaperones, prions, and
prion-like Q/N-rich proteins) may  break rigid network structures
similarly to lattice defects. Rigidity-seed nodes may  establish a rigid
cluster, and rigidity-promoting nodes may help its growth causing a
rigidity phase transition. Decreased creative node dynamics may
contribute to this process.
Creative nodes can be determined by their
inter-modular network position connecting
multiple modules at the same time and by their
extremely large dynamics.
[11,82,110,113,116,119–122]
Pulsation of large/small (or
fuzzy/compact) network cores
Larger/fuzzy network cores (i.e. a larger central and dense network
segments) increase system robustness, evolvability and plasticity.
Decreased network core size and/or increased core compactness may
increase the controllability of the system.
Network core size can be calculated by several
methods both for undirected and directed
(bow-tie) core-periphery networks.
[112]
Alternating ‘stratus’/‘cumulus’
(fuzzy/well-separated) network
modules
Fuzzy network modules have a large overlap, and form a structure
resembling to that of flat, dense, dark, low-lying, stratus clouds. This
plastic structure dissipates perturbations well. Well-defined,
separated network modules have a structure resembling to that of
puffy, white, cumulus clouds. This locally rigid structure develops after
stress, and displays reduced perturbation dissipation.
Network modularization methods detecting
overlapping modules may be used to assess the
separation of network modules. Methods detecting
extensive (pervasive) overlaps are especially good
for  this purpose.
[18,116–118,124]
Alternating plastic/rigid network
topologies
All the above changes may  lead to alternating plastic and rigid
network structures. Changing sub-cellular localizations may  often
contribute to changes in network plasticity/rigidity.
Network rigidity and rigid network clusters may
be calculated by generalized pebble game models.
[3,10–12]
(B) Changes in network environment
Alternating larger/smaller intracellular
water content
The more than a dozen known human aquaporin water transporters
have differential effects on tumor development. Increased intracellular
water may  act as “lubricant” increasing system plasticity, while
decreased intracellular water content may increase molecular
crowding and thus network rigidity.
Intracellular water content may  be measured by
several experimental methods such as nuclear
magnetic resonance spectroscopy. Water-induced
changes in molecular network dynamics may  be
calculated using protein dynamic models and their
consequences of interactome, signaling network
and metabolic network dynamics.
[114,115]
(C) Consequent changes in the quasi-potential (epigenetic) landscape of cancer stem cells
Alternating smooth/rough
quasi-potential (epigenetic)
landscape of cancer cell networks
All the above changes may  help the alternation of a smooth
quasi-potential (epigenetic) landscape characterized by “shallow”
cancer attractors and a rough quasi-potential (epigenetic) landscape
characterized by “deep” cancer attractors.
The state space landscape and network attractors
can be calculated from analytical models and
simulations of network dynamics.
[5,7,118,123,124]
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etwork influence strategy shifts the malfunctioning network of a
ore differentiated cell back to its normal state. This strategy is
seful when attacking rigid networks.
Since cancer stem cells cycle between plastic and rigid states
Fig. 1, Table 4) conventional chemotherapeutic interventions (tar-
eting plastic networks [3]) only shift the plastic/rigid cycle of
ancer stem cells towards the rigid state. For the eradication of can-
er stem cells a multi-target therapy is required which attacks their
lastic state with “central hit-type” component and their rigid state
ith a “network influence-type” component at the same time. Suc-
essful cancer stem cell eradication requires a network approach
ll the more, since the network influence strategy requires a multi-
arget approach by itself [3,123]. Moreover, efficient targeting of
igid networks (corresponding to quiescent cancer stem cells) often
equires an indirect approach, where e.g. neighbors of the real tar-
et are targeted. These drugs are called allo-network drugs and can
lso be identified using network-related methods [3,127].
An alternative therapeutic strategy is to “lock” cancer stem cells
ither in their plastic/proliferative, or in their rigid/quiescent state.
uch an intervention has to be followed by a lethal hit of the par-
icular, “locked” state of the cancer stem cell.
We strongly believe that a detailed analysis of cancer stem cell
etwork topology and dynamics based on single cell data will offer
 great help to delineate those drug combinations or multi-target
rugs, which act minimally on 3 different targets (one attacking the
lastic and two the rigid network-related cancer stem cell pheno-
ypes). It will be an important question of further studies, which
hronological order and duration of the drug combinations will
orm the most efficient anti-cancer stem cell therapy.
. Conclusions and perspectives
In conclusion, in this review first we summarized additional
ieces of evidence (Table 1) supporting our earlier proposal
3,11,12] that the major trend of malignant transformation is a
wo-phase process, where an initial increase of network plastic-
ty is followed by a decrease of network plasticity at late stages of
arcinogenesis. We  showed how environmental changes increase
he adaptation potential of cancer cells leading to the bypass of
ellular senescence and to the development of cancer stem cells
Table 2). We  proposed that cancer stem cells are characterized
y an extremely large evolvability helped by their repeated transi-
ions between plastic (proliferative, symmetrically dividing) and
igid (quiescent, asymmetrically dividing, often more invasive)
henotypes (Table 3, Fig. 1). Thus, cancer stem cells reverse and
eplay cancer development multiple times. Several hypothetical
etwork behaviors were described (Table 4), which may  explain
he extremely high evolvability of cancer stem cells. Network rigid-
ty/plasticity markers may  help to develop novel biomarkers of
ancer stem cells. “Locking” cancer stem cells either in their plas-
ic/proliferative, or in their rigid/quiescent state, or combination
r multi-target therapies involving a “central hit” and two “net-
ork influence” components [3] may  overcome the Nietzschean
ilemma of cancer stem cell targeting: “what does not kill me
akes me  stronger”.
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